IO Biotech Inc (IOBT) USD0.001
2.50%- This stock can be held in a
Stocks and Shares ISA
$0.01
(1.12%)$0.01
(1.12%)Company Information
About this company
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Key people
Key facts
- EPICIOBT
- LocationDenmark
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS4497781090
- Market cap$59.82m
- Employees80
- Shares in issue65.88m
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.